Deals· August 3, 2026 · 15 min read
Neurocrine's $2.9 Billion Soleno Acquisition: Vykat XR and the Prader-Willi Franchise
By Ran Chen#M&A#Rare Disease#Orange Book
Topic
Orphan Drug
Orphan drug designation, exclusivity, rare-disease launch planning, payer evidence needs, and access implications.
Deals· July 22, 2026 · 18 min read
Vertex's $10B Crinetics Acquisition: Paltusotine and Rare Endocrine Bet
By Ran Chen#M&A#Orphan Drug#Rare Disease
Specialty· July 7, 2026 · 21 min read
Voranigo (vorasidenib) Glioma Access: Pricing, Biomarker Testing, and Payer PA
By Ran Chen#Oncology#Orphan Drug#Prior Authorization
Policy· June 30, 2026 · 18 min read
China Drug Trial Data Protection (NMPA 2026 No.47): Exclusivity and BD Strategy
By Ran Chen#China#NMPA#Regulatory
Biosimilars· June 21, 2026 · 6 min read